Navigation Links
First Awards Made by London Genetics' Proof-of-Concept Fund
Date:2/24/2010

LONDON, February 24, 2010 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease. Financial details were not disclosed.

The purpose of projects funded by the POC fund is to illustrate the value the genetic data and resources within LGL's seven academic founding partners can add to drug discovery and clinical development. Typical funded projects are expected to involve:

    - Identification of disease genes and/or signalling pathways for use in
      target selection or drug reprofiling; or

    - Characterisation of disease genes or signalling pathways to inform risk
      management strategies, define patient criteria for inclusion in studies
      and stratified clinical study designs; or

    - Identification of potential markers of medicine efficacy and/or safety
      response.

Any intellectual property generated is expected to be retained by the institution, with a return to London Genetics upon its exploitation. The company's founding partners are all academic and medical centres with significant clinical and genetic expertise.

The immunotherapy project will investigate genetic regulation of production of natural killer cells, which are involved in protection against diseases from cancer to malaria. The second team will be involved in identifying and validating gene variants associated with the weight gain that often occurs in patients taking atypical antipsychotics for the treatment of schizophrenia. The cardiovascular project will look at drug target validation by using gene variants as a model of target modification.

Dominique Kleyn, CEO of London Genetics, said, 'We are delighted to be making these proof-of-concept awards which should provide further validation of our business model, and highlight our links with first-class academic teams. The biopharmaceutical industry is realising the potential of pharmacogenetics in helping it meet the myriad of challenges it faces, as we discuss in a recent MedNous commentary [1].'

    1. Why Pharmacogenetics is important to Pharma. MedNous January 2010
       Volume 4 No 1 p 3


    Notes to Editors:
    About London Genetics

London Genetics Limited, a not-for-profit company, is an expert in the use of pharmacogenetics in clinical drug discovery and development. Established in 2007 with funding from the London Development Agency, its seven founding partners are leading London academic and medical institutions with clinical and genetic expertise and significant patient resources. The company provides pharmaceutical and biotechnology companies with access to this expertise and resource, as well as providing strategic advice on the application of pharmacogenetics for successful drug development. LGL has broad therapeutic expertise with a focus on cardiovascular disease and drug side-effects of a cardiovascular nature. Recent agreements developed by London Genetics include a collaboration between the International Serious Adverse Events Consortium, St George's University of London and the Drug Safety Research Unit at Southampton, UK. The parties are working on genetic markers for drug-induced cardiac arrhythmia. LGL is based at the Imperial College Incubator in London, and has ISO 9001 accreditation. For further information, please go to http://www.londongeneticslimited.com

About pharmacogenetics

Genetic differences between individuals mean that drug response rates are often variable across a population, and this has significant implications for healthcare cost effectiveness. Pharmocogenetics, the study of the clinical consequences of genetic differences in the way people metabolise and respond to drugs, is expected to generate better understanding of how drugs work in the body, and therefore give insight into how to develop more efficacious and safer drugs. It also has implications for product life cycle management and the revitalisation of drugs which previously failed in clinical trials. With drug development costs rising and R&D productivity falling, plus increased regulator focus on safety and cost-effectiveness, pharmacogenetics is expected to become increasingly important in drug development. The FDA and the EMEA have recognised this in their Critical Path Initiative and Road Map respectively.

    For further information or to meet us at conferences please contact:

    London Genetics Ltd

    Dominique Kleyn, CEO
    +44(0)207-594-1838

    Emma Palmer Foster, Strategic Communications Consultant
    +44(0)7880-787185

    communications@londongenetics.com

SOURCE London Genetics Ltd

Back to top
'/>"/>
SOURCE London Genetics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves First New Inhaled Antibiotic for CF in More Than a Decade
2. As Biopharma Companies Reshape Sales Model, Most See Resetting Territory Size and Implementing Individualized Call Plans as First Steps Toward Change, According to New Research From Best Practices, LLC
3. Bedford Laboratories(TM) First To Manufacture Generic Indomethacin for Injection USP
4. Siemens Hosts First In a Series of Free Virtual Healthcare IT Conferences
5. Native Remedies NutraRx Brand of Natural Products for Medical Practitioners Among First to Earn Prestigious Emerson EQP Seal
6. CEL-SCI Corporation Reports First Quarter 2010 Financial Results
7. Free Prescription Coupons from FirstRxSavings.com Help Doctors to Evaluate Patients Reactions to Medications
8. Mount Vernon Cancer Centre Becomes First NHS Facility to Acquire a CyberKnife System
9. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
10. PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
11. Medical University of South Carolina First To Test New Heart Imaging Method To Detect Coronary Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
(Date:4/27/2016)... 2016 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends, and ... global skincare devices market was valued at US$ 7,255.8 ... a CAGR of 10.1% from 2015 to 2023 to ... the full Skincare Devices Market (Treatment Device - LED Therapy ...
(Date:4/27/2016)... NEW DELHI , April 27, 2016 ... CSR initiative to save newborns ... ,s hospital for women & newborns in collaboration with Breast ... has launched the first Pasteurized Human Milk Bank, ,Amaara, in ... the best nutritional food source for infants and should be ...
Breaking Medicine Technology:
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Dr. ... cosmetic dental treatments to improve smiles. Cosmetic dentistry is a fast-growing field as more ... This offer allows patients to learn more about the options currently available to them ...
(Date:4/29/2016)... Grants Pass, OR (PRWEB) , ... April 29, 2016 , ... ... nutritionists suggest dinner as the meal to miss. That was among the many new ... True Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny ...
(Date:4/29/2016)... ... ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of 100 on Tampa ... for Tampa’s Best Places to Work. They were ranked in the Big Category, which ... our team,” says RMS Human Resources Manager Irene Miller. “We work hard to build ...
(Date:4/29/2016)... ... , ... Nike Softball Camp at the College of Brockport in New York ... aged 10-18. All facets of the game will be covered; hitting, fielding, base-running, and ... of the finest softball facilities in the region. The outstanding professional college staff complement ...
(Date:4/29/2016)... ... April 29, 2016 , ... HEALTHCAREfirst ... and coding services, and Deyta Analytics, recently announced the recipients of the fourth ... of quality as measured from the caregiver’s point of view. The official list ...
Breaking Medicine News(10 mins):